Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.
By S. Yusuf, S. Mehta, S. Chrolavicius, Rizwan Afzal, Janice Pogue, C. Granger, A. Budaj, R. Peters, J. Bassand, L. Wallentin and 2 more. Journal of the American Medical Association (JAMA), 2006
870 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Internal Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/51f6cbba41dc1d277cd8d438f848612805e142f8
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
- G. Fonarow
- Jeroen J. Bax
- J. Halperin
- Gerasimos Filippatos
- Hani Jneid
- Judith Hochman
- Allan S. Jaffe
- M. Creager
In Internal Medicine
In Surgery
Citations in the corpus
- 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014, methodology): “Patients undergoing PCI who have previously received a loading dose of 300 mg of clopidogrel and are on a 75-mg daily maintenance dose should receive another 300-mg loading dose.(315) There are no data appropriate for prasugrel because this drug is administered before PCI.”
- 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (2008, methodology): “, streptokinase) seen with all 3 of the new anticoagulation regimens led the writing group to recommend the use of an anticoagulant across the spectrum of fibrinolytic agents in common clinical use.(6,7,70,76,77) When moving to PCI after fibrinolytic therapy, those patients who received upstream UFH”